
## **Richard Barohn**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10744410/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	and Patient/Parent Global Activity, Manuaĺ Muscle Tésting (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (Câ€HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SFâ€36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI),	3.4	288
2	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
3	Approach to Peripheral Neuropathy and Neuronopathy. Seminars in Neurology, 1998, 18, 7-18.	1.4	98
4	Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Molecular Genetics and Metabolism, 2012, 107, 456-461.	1.1	93
5	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology. 2017. 69. 898-910.	5.6	52
6	NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 601-609.	1.7	49
7	Clinical features of <scp>LRP4</scp> /agrinâ€antibody–positive myasthenia gravis: A multicenter study. Muscle and Nerve, 2020, 62, 333-343.	2.2	46
8	Inclusion Body Myositis. Seminars in Neurology, 2012, 32, 237-245.	1.4	43
9	Cryptogenic Sensory and Sensorimotor Polyneuropathies. Seminars in Neurology, 1998, 18, 105-111.	1.4	41
10	Idiopathic Inflammatory Myopathies. Seminars in Neurology, 2012, 32, 227-236.	1.4	37
11	A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease. Orphanet Journal of Rare Diseases, 2017, 12, 144.	2.7	29
12	Practice advisory: Thymectomy for myasthenia gravis (practice parameter update). Neurology, 2020, 94, 705-709.	1.1	29
13	A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 345-352.	1.7	26
14	North America and South America (NA-SA) neuropathy project. International Journal of Neuroscience, 2013, 123, 563-567.	1.6	24
15	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
16	Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Statistics in Medicine, 2015, 34, 1134-1149.	1.6	23
17	Distal Myopathies and Dystrophies. Seminars in Neurology, 1993, 13, 247-255.	1.4	19
18	Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients. Behavioural Neurology, 2018, 2018, 1-7.	2.1	19

**RICHARD BAROHN** 

#	Article	IF	CITATIONS
19	Phase <scp>2B</scp> randomized controlled trial of <scp>NP001</scp> in amyotrophic lateral sclerosis: Preâ€specified and post hoc analyses. Muscle and Nerve, 2022, 66, 39-49.	2.2	16
20	A Phonetic Complexity-Based Approach for Intelligibility and Articulatory Precision Testing: A Preliminary Study on Talkers With Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research, 2018, 61, 2205-2214.	1.6	15
21	An instrumented timed up and go in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2018, 57, 503-506.	2.2	13
22	Learning from the past: reflections on recently completed myasthenia gravis trials. Annals of the New York Academy of Sciences, 2018, 1412, 5-13.	3.8	11
23	Review process for IVIg treatment. Neurology: Clinical Practice, 2018, 8, 429-436.	1.6	9
24	Frontiers: Integration of a Research Participant Registry with Medical Clinic Registration and Electronic Health Records. Clinical and Translational Science, 2015, 8, 405-411.	3.1	8
25	Distal Myopathies. Seminars in Neurology, 1999, 19, 45-58.	1.4	6
26	Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials. Statistics in Biopharmaceutical Research, 2019, 11, 375-386.	0.8	5